Table 2. Results of univariate analysis of prognostic factors.

Factor	n of patients	2-Yr OS		2-Yr RFS		2-Yr LRFS		2-Yr DRFS
		% (95% CI)	p-value	% (95% CI)	p-value	% (95% CI)	p-value	% (95% CI)	p-value
Gender
Female	35	38 (22–55)	.38	30 (12–49)	.504	NA	.876	33 (12–54)	.027
Male	48	27 (15–40)		35 (19–52)		57 (37–76)		55 (35–75)
Age at diagnosis
≤60 yrs	33	27 (15–40)	.182	35 (19–52)	.959	45 (27–64)	.023	54 (34–75)	.125
>60 yrs	50	38 (21–55)		31 (11–50)		NA		36 (16–56)
Histology
SCC	30	30 (18–43)	.658	32 (17–47)		60 (43–77)	.746	38 (21–55)	.059
Other (ADC,…)	53	33 (16–50)		34 (12–57)	.559	NA		58 (31–85)
Tumor size
≤40 mm	45	26 (12–40)	.435	26 (8–44)	.506	NA	.055	36 (12–60)	.788
>40 mm	38	36 (22–51)		39 (21–56)		66 (47–85)		52 (33–70)
n of nodal stations involved
≤1	33	33 (19–46)	.612	29 (14–44)	.246	NA	.09	43 (25–61)	.359
>1	50	30 (14–46)		42 (20–64)		67 (42–93)		52 (28–76)
n of positive nodes
≤1	17	32 (21–44)	.884	36 (22–50)	.816	NA	.396	52 (35–68)	.555
>1	66	NA		23 (0–49)		58 (21–96)		NA
Surgical margins
Negative	71	37 (26–49)	.016	37 (24–50)	.458	59 (45–73)	.753	51 (36–66)	.171
Positive	12	18 (8–27)		NA		NA		NA
ECE
Negative	69	35 (23–47)	.357	42 (27–57)	.003	71 (56–86)	<.001	49 (33–64)	.517
Positive	14	22 (0–47)		15 (4–30)		NA		NA
Chemotherapy
No	48	27 (14–40)	.055	33 (15–50)	.233	55 (36–73)	.162	49 (28–71)	.686
Yes	35	38 (21–54)		33 (14–51)		NA		41 (21–61)
Radiotherapy
No	44	21 (9–33)	.002	NA	.013	NA	<.001	NA	.569
Yes	39	43 (28–59)		47 (29–65)		77 (60–94)		51 (33–69)

p-value for each variable was calculated using the log-rank test, limited to patients for whom data were available.

Abbreviations: ADC, adenocarcinoma; CI, confidence interval; DRFS, distant recurrence-free survival; ECE, extracapsular extension; LRFS, local recurrence-free survival; NA, not available; OS, overall survival; RFS, recurrence-free survival; SCC, squamous cell carcinoma.